Insider trading

Period: 120 months Stock: ONC Plan: Not stated × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

297 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

297 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

297 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

297 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
297 decisions over 120 months Remove this filter
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
297 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

297 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
8 Mar 2023
Wang Xiaodong Director
Sold, plan not stated 8×
$15.29M 67,635 at 226.03
100%
Sold half or more
1 Mar 2023
Wang Julia Aijun Chief Financial Officer
Sold, plan not stated
$82.39K 343 at 240.21
100%
Sold half or more
12 Jan 2023
Wang Xiaodong Director · indirect
Sold, plan not stated 2×
$1.30M 5,000 at 260.52
100%
Sold half or more
11 Jan 2023
Wang Xiaodong Director
Sold, plan not stated 4×
$631.65K 2,500 at 252.66
100%
Sold half or more
10 Jan 2023
OYLER JOHN Chief Executive Officer · indirect
Sold, plan not stated 10×
$3.38M 13,594 at 248.51
100%
Sold half or more
10 Jan 2023
OYLER JOHN Chief Executive Officer
Sold, plan not stated 5×
$1.69M 6,797 at 248.52
100%
Sold half or more
10 Jan 2023
Wang Xiaodong Director
Sold, plan not stated
$400.15K 1,600 at 250.09
100%
Sold half or more
9 Jan 2023
Wang Xiaodong Director
Sold, plan not stated
$225.00K 900 at 250.00
100%
Sold half or more
29 Dec 2022
OYLER JOHN Chief Executive Officer · indirect
Sold, plan not stated 4×
$770.80K 3,434 at 224.46
100%
Sold half or more
29 Dec 2022
OYLER JOHN Chief Executive Officer
Sold, plan not stated 2×
$385.17K 1,716 at 224.46
100%
Sold half or more
28 Dec 2022
OYLER JOHN Chief Executive Officer · indirect
Sold, plan not stated 2×
$164.72K 733 at 224.73
100%
Sold half or more
28 Dec 2022
OYLER JOHN Chief Executive Officer
Sold, plan not stated
$82.47K 367 at 224.73
100%
Sold half or more
27 Dec 2022
OYLER JOHN Chief Executive Officer · indirect
Sold, plan not stated 2×
$502.19K 2,239 at 224.29
100%
Sold half or more
27 Dec 2022
OYLER JOHN Chief Executive Officer
Sold, plan not stated
$251.21K 1,120 at 224.29
100%
Sold half or more
13 Dec 2022
Wang Xiaodong Director · indirect
Sold, plan not stated 3×
$636.72K 3,013 at 211.33
100%
Sold half or more
15 Nov 2022
OYLER JOHN Chief Executive Officer
Sold, plan not stated 7×
$5.17M 25,000 at 206.84
100%
Sold half or more
15 Nov 2022
OYLER JOHN Chief Executive Officer · indirect
Sold, plan not stated 6×
$1.02M 4,928 at 206.82
100%
Sold half or more
15 Nov 2022
Wang Xiaodong Director · indirect
Sold, plan not stated
$417.54K 1,987 at 210.14
100%
Sold half or more
21 Sep 2022
OYLER JOHN Chief Executive Officer · indirect
Sold, plan not stated 12×
$2.92M 19,480 at 149.99
100%
Sold half or more
20 Sep 2022
OYLER JOHN Chief Executive Officer · indirect
Sold, plan not stated 6×
$4.68M 30,520 at 153.50
100%
Sold half or more
8 Aug 2022
Wang Xiaodong Director
Sold, plan not stated 5×
$1.22M 6,060 at 201.25
100%
Sold half or more
5 Aug 2022
Wang Xiaodong Director · indirect
Sold, plan not stated 10×
$969.27K 5,000 at 193.85
100%
Sold half or more
5 Aug 2022
Wang Xiaodong Director
Sold, plan not stated 10×
$969.26K 5,000 at 193.85
100%
Sold half or more
1 Jul 2022
Wang Julia Aijun Chief Financial Officer
Sold, plan not stated
$46.76K 295 at 158.50
100%
Sold half or more
27 Jun 2022
Wang Lai Global Head of R&D
Sold, plan not stated
$81.21K 458 at 177.32
100%
Sold half or more
21 Jun 2022
Wu Xiaobin President, COO & GM China
Sold, plan not stated
$145.80K 1,010 at 144.36
100%
Sold half or more
21 Jun 2022
Wang Lai Global Head of R&D
Sold, plan not stated
$107.73K 723 at 149.01
100%
Sold half or more
17 Jun 2022
Wu Xiaobin President, COO & GM China
Sold, plan not stated
$80.69K 578 at 139.60
36.4%
17 Jun 2022
Wang Lai Global Head of R&D
Sold, plan not stated
$62.03K 445 at 139.40
38.1%
17 Jun 2022
Wang Julia Aijun Chief Financial Officer
Sold, plan not stated
$22.00K 161 at 136.64
100%
Sold half or more
6 Jun 2022
Wu Xiaobin President, COO & GM China
Sold, plan not stated
$484.20K 3,410 at 141.99
100%
Sold half or more
6 Jun 2022
Wang Lai Global Head of R&D
Sold, plan not stated
$93.72K 660 at 142.00
100%
Sold half or more
5 May 2022
Wu Xiaobin President, COO & GM China
Sold, plan not stated 7×
$1.11M 6,725 at 164.35
100%
Sold half or more
14 Dec 2021
Huang Jane CMO, Hematology
Sold, plan not stated 6×
$417.21K 1,500 at 278.14
100%
Sold half or more
1 Dec 2021
Huang Jane CMO, Hematology
Sold, plan not stated 2×
$377.49K 1,049 at 359.86
100%
Sold half or more
17 Nov 2021
Huang Jane CMO, Hematology
Sold, plan not stated 9×
$572.00K 1,500 at 381.34
100%
Sold half or more
9 Nov 2021
Wu Xiaobin President, COO & GM China
Sold, plan not stated 9×
$855.04K 2,334 at 366.34
100%
Sold half or more
8 Nov 2021
Wang Xiaodong Director
Sold, plan not stated 27×
$3.15M 9,000 at 349.93
100%
Sold half or more
8 Nov 2021
Wu Xiaobin President, COO & GM China
Sold, plan not stated 13×
$2.73M 7,666 at 355.81
100%
Sold half or more
19 Oct 2021
Huang Jane CMO, Hematology
Sold, plan not stated 7×
$559.16K 1,500 at 372.78
100%
Sold half or more
20 Sep 2021
Huang Jane CMO, Hematology
Sold, plan not stated 14×
$2.39M 6,000 at 397.96
100%
Sold half or more
15 Sep 2021
OYLER JOHN Chief Executive Officer
Sold, plan not stated 8×
$9.86M 26,158 at 377.10
100%
Sold half or more
15 Sep 2021
OYLER JOHN Chief Executive Officer
Sold, plan not stated
$5.58M 190,203 at 29.31
9.9%
14 Sep 2021
OYLER JOHN Chief Executive Officer
Sold, plan not stated 9×
$13.90M 37,877 at 367.02
100%
Sold half or more
14 Sep 2021
OYLER JOHN Chief Executive Officer
Sold, plan not stated
$4.45M 157,600 at 28.22
6.5%
13 Sep 2021
Huang Jane CMO, Hematology
Sold, plan not stated 8×
$4.62M 12,901 at 358.14
100%
Sold half or more
10 Sep 2021
AMGEN INC 10% owner
Bought
$50.00M 165,529 at 302.06
0.9%
First buy on file
2 Sep 2021
OYLER JOHN Chief Executive Officer
Sold, plan not stated 9×
$8.04M 24,499 at 328.21
100%
Sold half or more
2 Sep 2021
Huang Jane CMO, Hematology
Sold, plan not stated
$178.31K 545 at 327.18
100%
Sold half or more
1 Sep 2021
OYLER JOHN Chief Executive Officer
Sold, plan not stated 4×
$8.31M 25,501 at 325.73
100%
Sold half or more
Showing 1–50 of 297. Page 1 of 6 Older →